Skip to content
The Policy VaultThe Policy Vault

SoriluxMedical Mutual

Plaque psoriasis

Preferred products

  • Generic calcipotriene cream
  • Generic calcipotriene ointment
  • Generic calcipotriene solution

Initial criteria

  • If the patient has tried a preferred medication, then authorization for a non-preferred medication may be given.
  • If the patient is < 18 years of age, approve generic calcipotriene-betamethasone dipropionate ointment, Taclonex ointment, calcipotriene foam (authorized generic), Enstilar, or Sorilux.

Reauthorization criteria

  • Step Therapy Exception Criteria: Approve for 1 year if the patient meets the following (A, B, or C):
  • A. The patient has an atypical diagnosis and/or unique patient characteristics which prevent use of all preferred agents. OR
  • B. The patient has a contraindication to all preferred agents. OR
  • C. The patient is continuing therapy with the requested non-preferred agent after being stable for at least 90 days AND meets ONE of the following:
  • 1. The patient has at least 130 days of prescription claims history on file and claims history supports that the patient has received the requested non-preferred agent for 90 days within a 130-day look-back period AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product). OR
  • 2. When 130 days of the patient’s prescription claims history file is unavailable for verification, the prescriber must verify that the patient has been receiving the requested non-preferred agent for 90 days AND that the patient has been receiving the requested non-preferred agent via paid claims AND there is no generic equivalent available for the requested nonpreferred product (i.e. AA-rated or AB-rated to the requested nonpreferred product).

Approval duration

initial 1 year; extended 2 years; continuation 1 year